- Scope of the procurement
- Lot 1 – C1 Esterase – Recombinant four (acute treatment)
- Lot 3 - C1 Esterase – Plasma derived four (prophylaxis treatment)
- Lot 6 - Lanadelumab
- Lot 7 - Berotralstat
- Lot 2 - C1 Esterase – Plasma derived four (acute treatment)
- Lot 4 - C1 Esterase – Plasma derived Subcut (prophylaxis treatment)
- Lot 5 - Icatibant
Section one: Contracting authority
one.1) Name and addresses
NHS England
Quarry House
Leeds
LS2 7UE
Contact
Philip Grieve
Country
United Kingdom
NUTS code
UKE - Yorkshire and the Humber
Internet address(es)
Main address
Buyer's address
one.2) Information about joint procurement
The contract is awarded by a central purchasing body
one.4) Type of the contracting authority
Ministry or any other national or federal authority
one.5) Main activity
Health
Section two: Object
two.1) Scope of the procurement
two.1.1) Title
NHS National Framework Agreement for the Supply of products for the management of Hereditary Angioedema
Reference number
CM/PHS/19/5583
two.1.2) Main CPV code
- 33600000 - Pharmaceutical products
two.1.3) Type of contract
Supplies
two.1.4) Short description
National Framework Agreement for the supply of products for the management of Hereditary Angioedema. The framework will commence on 1 July 2022 for a period of 18 months with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months.
Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for a list of the purchasing points.
two.1.6) Information about lots
This contract is divided into lots: Yes
two.1.7) Total value of the procurement (excluding VAT)
Value excluding VAT: £198,666,666
two.2) Description
two.2.1) Title
Lot 1 – C1 Esterase – Recombinant IV (acute treatment)
Lot No
1
two.2.2) Additional CPV code(s)
- 33600000 - Pharmaceutical products
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
Main site or place of performance
ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Northern Ireland, Dept of Health and Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of the above
two.2.4) Description of the procurement
NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. Offer reference number: CM/PHS/19/5583. Period of framework agreement: 1 July 2022 to 31 December 2023 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months
two.2.5) Award criteria
Quality criterion - Name: Security of Supply / Weighting: 20%
Quality criterion - Name: Ease of Use / Weighting: 10%
Price - Weighting: 70%
two.2.11) Information about options
Options: Yes
Description of options
Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2.14) Additional information
Price is not the only award criterion and all criteria are stated only in the procurement documents.
Additional CPV Codes:
33141520 – Plasma Extracts
33141510 – Blood Products
two.2) Description
two.2.1) Title
Lot 3 - C1 Esterase – Plasma derived IV (prophylaxis treatment)
Lot No
3
two.2.2) Additional CPV code(s)
- 33600000 - Pharmaceutical products
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
Main site or place of performance
ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above
two.2.4) Description of the procurement
NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. Offer reference number: CM/PHS/19/5583. Period of framework agreement: 1 July 2022 to 31 December 2023 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months
two.2.5) Award criteria
Quality criterion - Name: Security of Supply / Weighting: 20%
Quality criterion - Name: Ease of Use / Weighting: 10%
Price - Weighting: 70%
two.2.11) Information about options
Options: Yes
Description of options
Option or options to extend at the Authority's discretion for a period or periods up to a a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2.14) Additional information
Price is not the only award criterion and all criteria are stated only in the procurement documents.
Additional CPV Codes:
33141520 – Plasma Extracts
33141510 – Blood Products
two.2) Description
two.2.1) Title
Lot 6 - Lanadelumab
Lot No
6
two.2.2) Additional CPV code(s)
- 33600000 - Pharmaceutical products
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
Main site or place of performance
ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above
two.2.4) Description of the procurement
NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. Offer reference number: CM/PHS/19/5583. Period of framework agreement: 1 July 2022 to 31 December 2023 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months
two.2.5) Award criteria
Quality criterion - Name: Security of Supply / Weighting: 20%
Quality criterion - Name: Ease of Use / Weighting: 10%
Price - Weighting: 70%
two.2.11) Information about options
Options: Yes
Description of options
Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2.14) Additional information
Price is not the only award criterion and all criteria are stated only in the procurement documents.
Additional CPV Codes:
33141520 – Plasma Extracts
33141510 – Blood Products
two.2) Description
two.2.1) Title
Lot 7 - Berotralstat
Lot No
7
two.2.2) Additional CPV code(s)
- 33600000 - Pharmaceutical products
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
Main site or place of performance
ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above
two.2.4) Description of the procurement
NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. Offer reference number: CM/PHS/19/5583. Period of framework agreement: 1 July 2022 to 31 December 2023 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months
two.2.5) Award criteria
Quality criterion - Name: Security of Supply / Weighting: 20%
Quality criterion - Name: Ease of Use / Weighting: 10%
Price - Weighting: 70%
two.2.11) Information about options
Options: Yes
Description of options
Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2.14) Additional information
Price is not the only award criterion and all criteria are stated only in the procurement documents.
Additional CPV Codes:
33141520 – Plasma Extracts
33141510 – Blood Products
two.2) Description
two.2.1) Title
Lot 2 - C1 Esterase – Plasma derived IV (acute treatment)
Lot No
2
two.2.2) Additional CPV code(s)
- 33600000 - Pharmaceutical products
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
Main site or place of performance
ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above
two.2.4) Description of the procurement
NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. Offer reference number: CM/PHS/19/5583. Period of framework agreement: 1 July 2022 to 31 December 2023 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months
two.2.5) Award criteria
Quality criterion - Name: Security of Supply / Weighting: 20%
Quality criterion - Name: Ease of Use / Weighting: 10%
Price - Weighting: 70%
two.2.11) Information about options
Options: Yes
Description of options
Option or options to extend at the Authority's discretion for a period or periods up to a a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2.14) Additional information
Price is not the only award criterion and all criteria are stated only in the procurement documents.
Additional CPV Codes:
33141520 – Plasma Extracts
33141510 – Blood Products
two.2) Description
two.2.1) Title
Lot 4 - C1 Esterase – Plasma derived Subcut (prophylaxis treatment)
Lot No
4
two.2.2) Additional CPV code(s)
- 33600000 - Pharmaceutical products
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
Main site or place of performance
ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above
two.2.4) Description of the procurement
NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. Offer reference number: CM/PHS/19/5583. Period of framework agreement: 1 July 2022 to 31 December 2023 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months
two.2.5) Award criteria
Quality criterion - Name: Security of Supply / Weighting: 20%
Quality criterion - Name: Ease of Use / Weighting: 10%
Price - Weighting: 70%
two.2.11) Information about options
Options: Yes
Description of options
Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2.14) Additional information
Price is not the only award criterion and all criteria are stated only in the procurement documents.
Additional CPV Codes:
33141520 – Plasma Extracts
33141510 – Blood Products
two.2) Description
two.2.1) Title
Lot 5 - Icatibant
Lot No
5
two.2.2) Additional CPV code(s)
- 33600000 - Pharmaceutical products
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
Main site or place of performance
ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Northern Ireland, Dept of Health and Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of the above
two.2.4) Description of the procurement
NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. Offer reference number: CM/PHS/19/5583. Period of framework agreement: 1 July 2022 to 31 December 2023 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months
two.2.5) Award criteria
Quality criterion - Name: Security of Supply / Weighting: 20%
Quality criterion - Name: Ease of Use / Weighting: 10%
Price - Weighting: 70%
two.2.11) Information about options
Options: Yes
Description of options
Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2.14) Additional information
Price is not the only award criterion and all criteria are stated only in the procurement documents.
Additional CPV Codes:
33141520 – Plasma Extracts
33141510 – Blood Products
Section four. Procedure
four.1) Description
four.1.1) Type of procedure
Open procedure
four.1.3) Information about a framework agreement or a dynamic purchasing system
The procurement involves the establishment of a framework agreement
four.1.8) Information about the Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement: Yes
four.2) Administrative information
four.2.1) Previous publication concerning this procedure
Notice number: 2022/S 000-003602
Section five. Award of contract
Contract No
CM/PHS/19/5583
Lot No
Lot 1 - C1 Esterase – Recombinant IV (acute treatment)
Title
Hereditary Angioedema. Lot 1 - C1 Esterase – Recombinant IV (acute treatment)
A contract/lot is awarded: Yes
five.2) Award of contract
five.2.1) Date of conclusion of the contract
20 June 2022
five.2.2) Information about tenders
Number of tenders received: 1
Number of tenders received from SMEs: 0
Number of tenders received from tenderers from other EU Member States: 0
Number of tenders received from tenderers from non-EU Member States: 1
Number of tenders received by electronic means: 1
The contract has been awarded to a group of economic operators: No
five.2.3) Name and address of the contractor
Pharming Group
Darwinweg, The Netherlands
Darwinweg
242333
Country
United Kingdom
NUTS code
- UK - United Kingdom
The contractor is an SME
No
five.2.4) Information on value of contract/lot (excluding VAT)
Initial estimated total value of the contract/lot: £1
Total value of the contract/lot: £1
Section five. Award of contract
Contract No
CM/PHS/19/5583
Lot No
3
Title
Lot 3 - C1 Esterase – Plasma derived IV (prophylaxis treatment)
A contract/lot is awarded: Yes
five.2) Award of contract
five.2.1) Date of conclusion of the contract
20 June 2022
five.2.2) Information about tenders
Number of tenders received: 1
Number of tenders received from SMEs: 0
Number of tenders received from tenderers from other EU Member States: 0
Number of tenders received from tenderers from non-EU Member States: 1
Number of tenders received by electronic means: 1
The contract has been awarded to a group of economic operators: No
five.2.3) Name and address of the contractor
Takeda UK Ltd
1 Kingdom Street
London
W2 6BD
Country
United Kingdom
NUTS code
- UK - United Kingdom
The contractor is an SME
No
five.2.4) Information on value of contract/lot (excluding VAT)
Initial estimated total value of the contract/lot: £1
Total value of the contract/lot: £1
Section five. Award of contract
Contract No
CM/PHS/19/5583
Lot No
6
Title
Hereditary Angioedema. Lot 6 - Lanadelumab
A contract/lot is awarded: Yes
five.2) Award of contract
five.2.1) Date of conclusion of the contract
20 June 2022
five.2.2) Information about tenders
Number of tenders received: 1
Number of tenders received from SMEs: 0
Number of tenders received from tenderers from other EU Member States: 0
Number of tenders received from tenderers from non-EU Member States: 1
Number of tenders received by electronic means: 1
The contract has been awarded to a group of economic operators: No
five.2.3) Name and address of the contractor
Takeda UK Ltd
1 Kingdom Street
London
W2 6BD
Country
United Kingdom
NUTS code
- UK - United Kingdom
The contractor is an SME
No
five.2.4) Information on value of contract/lot (excluding VAT)
Initial estimated total value of the contract/lot: £1
Total value of the contract/lot: £1
Section five. Award of contract
Contract No
CM/PHS/19/5583
Lot No
7
Title
Hereditary Angioedema. Lot 7 - Berotralstat
A contract/lot is awarded: Yes
five.2) Award of contract
five.2.1) Date of conclusion of the contract
20 June 2022
five.2.2) Information about tenders
Number of tenders received: 1
Number of tenders received from SMEs: 1
Number of tenders received from tenderers from other EU Member States: 1
Number of tenders received from tenderers from non-EU Member States: 0
Number of tenders received by electronic means: 1
The contract has been awarded to a group of economic operators: No
five.2.3) Name and address of the contractor
BioCryst Ireland Limited
Harcourt Centre, Harcourt Road
Dublin
2D02 HW77
Country
United Kingdom
NUTS code
- UK - United Kingdom
The contractor is an SME
Yes
five.2.4) Information on value of contract/lot (excluding VAT)
Initial estimated total value of the contract/lot: £1
Total value of the contract/lot: £1
Section five. Award of contract
Contract No
CM/PHS/19/5583
Lot No
Lot 2 - C1 Esterase – Plasma derived IV (acute treatment)
Title
Hereditary Angioedema. Lot 2 - C1 Esterase – Plasma derived IV (acute treatment)
A contract/lot is awarded: Yes
five.2) Award of contract
five.2.1) Date of conclusion of the contract
20 June 2022
five.2.2) Information about tenders
Number of tenders received: 2
Number of tenders received from SMEs: 0
Number of tenders received from tenderers from other EU Member States: 0
Number of tenders received from tenderers from non-EU Member States: 2
Number of tenders received by electronic means: 2
The contract has been awarded to a group of economic operators: No
five.2.3) Name and address of the contractor
CSL Behring UK Ltd
4 Milton Road, Haywards Heath
Haywards Heath
RH16 1AH
Country
United Kingdom
NUTS code
- UK - United Kingdom
The contractor is an SME
No
five.2.4) Information on value of contract/lot (excluding VAT)
Initial estimated total value of the contract/lot: £1
Total value of the contract/lot: £1
Section five. Award of contract
Contract No
CM/PHS/19/5583
Lot No
Lot 2 - C1 Esterase – Plasma derived IV (acute treatment)
Title
Hereditary Angioedema. Lot 2 - C1 Esterase – Plasma derived IV (acute treatment)
A contract/lot is awarded: Yes
five.2) Award of contract
five.2.1) Date of conclusion of the contract
20 June 2022
five.2.2) Information about tenders
Number of tenders received: 2
Number of tenders received from SMEs: 0
Number of tenders received from tenderers from other EU Member States: 0
Number of tenders received from tenderers from non-EU Member States: 2
Number of tenders received by electronic means: 2
The contract has been awarded to a group of economic operators: No
five.2.3) Name and address of the contractor
Takeda UK Ltd
1 Kingdom Street
London
W2 6BD
Country
United Kingdom
NUTS code
- UK - United Kingdom
The contractor is an SME
No
five.2.4) Information on value of contract/lot (excluding VAT)
Initial estimated total value of the contract/lot: £1
Total value of the contract/lot: £1
Section five. Award of contract
Contract No
CM/PHS/19/5583
Lot No
4
Title
Lot 4 - C1 Esterase – Plasma derived Subcut (prophylaxis treatment)
A contract/lot is awarded: Yes
five.2) Award of contract
five.2.1) Date of conclusion of the contract
20 June 2022
five.2.2) Information about tenders
Number of tenders received: 1
Number of tenders received from SMEs: 0
Number of tenders received from tenderers from other EU Member States: 0
Number of tenders received from tenderers from non-EU Member States: 1
Number of tenders received by electronic means: 1
The contract has been awarded to a group of economic operators: No
five.2.3) Name and address of the contractor
CSL Behring UK Ltd
4 Milton Road, Haywards Heath
Haywards Heath
RH16 1AH
Country
United Kingdom
NUTS code
- UK - United Kingdom
The contractor is an SME
No
five.2.4) Information on value of contract/lot (excluding VAT)
Initial estimated total value of the contract/lot: £1
Total value of the contract/lot: £1
Section five. Award of contract
Contract No
CM/PHS/19/5583
Lot No
5
Title
Hereditary Angioedema. Lot 5 - Icatibant
A contract/lot is awarded: Yes
five.2) Award of contract
five.2.1) Date of conclusion of the contract
20 June 2022
five.2.2) Information about tenders
Number of tenders received: 10
Number of tenders received from SMEs: 4
Number of tenders received from tenderers from other EU Member States: 0
Number of tenders received from tenderers from non-EU Member States: 10
Number of tenders received by electronic means: 10
The contract has been awarded to a group of economic operators: No
five.2.3) Name and address of the contractor
Martindale Pharma
Building A2 Glory Park, Glory Park Avenue
Wooburn Green
HP10 0DF
Country
United Kingdom
NUTS code
- UK - United Kingdom
The contractor is an SME
No
five.2.4) Information on value of contract/lot (excluding VAT)
Initial estimated total value of the contract/lot: £1
Total value of the contract/lot: £1
Section five. Award of contract
Contract No
CM/PHS/19/5583
Lot No
5
Title
Hereditary Angioedema. Lot 5 - Icatibant
A contract/lot is awarded: Yes
five.2) Award of contract
five.2.1) Date of conclusion of the contract
20 June 2022
five.2.2) Information about tenders
Number of tenders received: 10
Number of tenders received from SMEs: 4
Number of tenders received from tenderers from other EU Member States: 0
Number of tenders received from tenderers from non-EU Member States: 10
Number of tenders received by electronic means: 10
The contract has been awarded to a group of economic operators: No
five.2.3) Name and address of the contractor
Piramal Critical care Limited
Suite 4, Heathrow Boulevard
West Drayton
UB7 0DQ
Country
United Kingdom
NUTS code
- UK - United Kingdom
The contractor is an SME
Yes
five.2.4) Information on value of contract/lot (excluding VAT)
Initial estimated total value of the contract/lot: £1
Total value of the contract/lot: £1
Section five. Award of contract
Contract No
CM/PHS/19/5583
Lot No
5
Title
Hereditary Angioedema. Lot 5 - Icatibant
A contract/lot is awarded: Yes
five.2) Award of contract
five.2.1) Date of conclusion of the contract
20 June 2022
five.2.2) Information about tenders
Number of tenders received: 10
Number of tenders received from SMEs: 4
Number of tenders received from tenderers from other EU Member States: 0
Number of tenders received from tenderers from non-EU Member States: 10
Number of tenders received by electronic means: 10
The contract has been awarded to a group of economic operators: No
five.2.3) Name and address of the contractor
Wockhardt UK Limited
Ash Road North, Wrexham Industrial Estate
Wrexham
LL13 9UF
Country
United Kingdom
NUTS code
- UK - United Kingdom
The contractor is an SME
Yes
five.2.4) Information on value of contract/lot (excluding VAT)
Initial estimated total value of the contract/lot: £1
Total value of the contract/lot: £1
Section five. Award of contract
Contract No
CM/PHS/19/5583
Lot No
5
Title
Hereditary Angioedema. Lot 5 - Icatibant
A contract/lot is awarded: Yes
five.2) Award of contract
five.2.1) Date of conclusion of the contract
20 June 2022
five.2.2) Information about tenders
Number of tenders received: 10
Number of tenders received from SMEs: 4
Number of tenders received from tenderers from other EU Member States: 0
Number of tenders received from tenderers from non-EU Member States: 10
Number of tenders received by electronic means: 10
The contract has been awarded to a group of economic operators: No
five.2.3) Name and address of the contractor
Cipla
Bourne Business Park, Addlestone
Addlestone
KT15 2LE
Country
United Kingdom
NUTS code
- UK - United Kingdom
The contractor is an SME
No
five.2.4) Information on value of contract/lot (excluding VAT)
Initial estimated total value of the contract/lot: £1
Total value of the contract/lot: £1
Section five. Award of contract
Contract No
CM/PHS/19/5583
Lot No
5
Title
Hereditary Angioedema. Lot 5 - Icatibant
A contract/lot is awarded: Yes
five.2) Award of contract
five.2.1) Date of conclusion of the contract
20 June 2022
five.2.2) Information about tenders
Number of tenders received: 10
Number of tenders received from SMEs: 4
Number of tenders received from tenderers from other EU Member States: 0
Number of tenders received from tenderers from non-EU Member States: 10
Number of tenders received by electronic means: 10
The contract has been awarded to a group of economic operators: No
five.2.3) Name and address of the contractor
Takeda UK Ltd
1 Kingdom Street
London
W2 6BD
Country
United Kingdom
NUTS code
- UK - United Kingdom
The contractor is an SME
No
five.2.4) Information on value of contract/lot (excluding VAT)
Initial estimated total value of the contract/lot: £1
Total value of the contract/lot: £1
Section five. Award of contract
Contract No
CM/PHS/19/5583
Lot No
5
Title
Hereditary Angioedema. Lot 5 - Icatibant
A contract/lot is awarded: Yes
five.2) Award of contract
five.2.1) Date of conclusion of the contract
20 June 2022
five.2.2) Information about tenders
Number of tenders received: 10
Number of tenders received from SMEs: 4
Number of tenders received from tenderers from other EU Member States: 0
Number of tenders received from tenderers from non-EU Member States: 10
Number of tenders received by electronic means: 10
The contract has been awarded to a group of economic operators: No
five.2.3) Name and address of the contractor
Accord-UK Ltd
Whiddon Valley
Barnstaple
EX32 8NS
Country
United Kingdom
NUTS code
- UK - United Kingdom
The contractor is an SME
No
five.2.4) Information on value of contract/lot (excluding VAT)
Initial estimated total value of the contract/lot: £1
Total value of the contract/lot: £1
Section five. Award of contract
Contract No
CM/PHS/19/5583
Lot No
5
Title
Hereditary Angioedema. Lot 5 - Icatibant
A contract/lot is awarded: Yes
five.2) Award of contract
five.2.1) Date of conclusion of the contract
20 June 2022
five.2.2) Information about tenders
Number of tenders received: 10
Number of tenders received from SMEs: 4
Number of tenders received from tenderers from other EU Member States: 0
Number of tenders received from tenderers from non-EU Member States: 10
Number of tenders received by electronic means: 10
The contract has been awarded to a group of economic operators: No
five.2.3) Name and address of the contractor
Celix Pharma Ltd.
4 Cullera Close
Middlesex
HA6 3SE
Country
United Kingdom
NUTS code
- UK - United Kingdom
The contractor is an SME
Yes
five.2.4) Information on value of contract/lot (excluding VAT)
Initial estimated total value of the contract/lot: £1
Total value of the contract/lot: £1
Section six. Complementary information
six.4) Procedures for review
six.4.1) Review body
The High Court
Strand
London
WC2A 2LL
generaloffice@administrativecourtoffice.justice.gov.uk
Country
United Kingdom